Excitement is already building around a project to produce point-of-care gene sequencing, which would eliminate the need to send samples via the expensive, time-consuming, and inefficient clinical trial procedure. Pharma businesses are faced with the challenge of implementing costly molecular diagnostic procedures that have limited diagnostic uses, or "subtle differences," that may now be instantly detected. There is a dearth of skilled laboratory workers who are knowledgeable about and proficient in using these technologies. New technologies are not always deployed to the appropriate patients. Such technology is still not supported by the supply chain that ships samples from one clinical lab to another. Clinical trial costs are still high.